---
title: "BioVaxys Extends Private Placement Closing Date to February 14, 2025"
date: "2025-02-08 10:32:30"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioBioVaxys Technology ( (TSE:BIOV) ) has..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1306769920-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

BioVaxys Technology ( [(TSE:BIOV)](https://www.tipranks.com/stocks/tse:biov) ) has shared an announcement.

BioVaxys Technology Corp. has announced an extension to the closing date of its non-brokered private placement offering, originally set for February 7, 2025, and now extended to February 14, 2025. This extension aims to allow additional investors to engage in the final tranche, with proceeds intended for working capital. The announcement could enhance BioVaxys’ financial flexibility and operational capacity, potentially strengthening its market position and offering stakeholders a more robust platform for future developments.

**More about BioVaxys Technology**

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada. It focuses on developing novel immunotherapies using its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immunological fields. The company’s innovative DPX™ platform is designed to deliver antigens to lymph nodes, inducing strong and lasting immune responses, and its shares are traded on the Canadian Securities Exchange, Frankfurt Bourse, and quoted in the US on OTC Markets.

**YTD Price Performance:** -16.00%

**Average Trading Volume:** 500,057

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** $9.84M

Find detailed analytics on BIOV stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/tse:biov/stock-analysis).

Trending Articles:
------------------

* [Trump Settlement Would “Cripple” Paramount (NASDAQ:PARA)](https://www.tipranks.com/news/trump-settlement-would-cripple-paramount-nasdaqpara)
* [Ford (NYSE:F) Offers a Closer Look at Tariff Impact](https://www.tipranks.com/news/ford-nysef-offers-a-closer-look-at-tariff-impact)
* [New Rumors Emerge About Intel’s (NASDAQ:INTC) Next CEO](https://www.tipranks.com/news/new-rumors-emerge-about-intels-nasdaqintc-next-ceo)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/biovaxys-extends-private-placement-closing-date-to-february-14-2025)
